ATE413865T1 - Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür - Google Patents

Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür

Info

Publication number
ATE413865T1
ATE413865T1 AT04759681T AT04759681T ATE413865T1 AT E413865 T1 ATE413865 T1 AT E413865T1 AT 04759681 T AT04759681 T AT 04759681T AT 04759681 T AT04759681 T AT 04759681T AT E413865 T1 ATE413865 T1 AT E413865T1
Authority
AT
Austria
Prior art keywords
compositions
release
methods
acid esters
active ingredients
Prior art date
Application number
AT04759681T
Other languages
English (en)
Inventor
John Lipari
Michelle Long
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE413865T1 publication Critical patent/ATE413865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04759681T 2003-03-31 2004-03-19 Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür ATE413865T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/403,071 US20040191207A1 (en) 2003-03-31 2003-03-31 Alpha-hydroxy acid ester drug delivery compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE413865T1 true ATE413865T1 (de) 2008-11-15

Family

ID=32989847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759681T ATE413865T1 (de) 2003-03-31 2004-03-19 Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür

Country Status (14)

Country Link
US (1) US20040191207A1 (de)
EP (1) EP1608346B1 (de)
JP (2) JP5005339B2 (de)
AT (1) ATE413865T1 (de)
CA (1) CA2518918C (de)
CY (1) CY1108700T1 (de)
DE (1) DE602004017705D1 (de)
DK (1) DK1608346T3 (de)
ES (1) ES2317017T3 (de)
MX (1) MXPA05010607A (de)
PL (1) PL1608346T3 (de)
PT (1) PT1608346E (de)
SI (1) SI1608346T1 (de)
WO (1) WO2004093851A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
DE102010013064A1 (de) 2010-03-26 2011-12-15 Gabriele Blume Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3716954A1 (de) 2017-11-27 2020-10-07 Umecrine Cognition AB Pharmazeutische formulierung von 3-ethynyl-3-hydroxyandrostan-17-on-oxim
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492325A (en) * 1967-03-24 1970-01-27 Procter & Gamble Production of alpha-hydroxy acids and esters
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
CA2185600A1 (en) * 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
KR100366373B1 (ko) * 1997-07-01 2003-01-14 화이자 프로덕츠 인코포레이티드 가용화된 세트랄린 조성물
EP1039893B1 (de) * 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU4917900A (en) * 1999-05-07 2000-11-21 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
WO2000074652A1 (de) * 1999-06-02 2000-12-14 Hexal Ag Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Also Published As

Publication number Publication date
JP2012136521A (ja) 2012-07-19
US20040191207A1 (en) 2004-09-30
EP1608346B1 (de) 2008-11-12
DE602004017705D1 (de) 2008-12-24
JP2006522105A (ja) 2006-09-28
JP5592905B2 (ja) 2014-09-17
CA2518918C (en) 2011-08-09
JP5005339B2 (ja) 2012-08-22
SI1608346T1 (sl) 2009-04-30
CY1108700T1 (el) 2014-04-09
CA2518918A1 (en) 2004-11-04
MXPA05010607A (es) 2005-11-23
WO2004093851A1 (en) 2004-11-04
DK1608346T3 (da) 2009-01-26
ES2317017T3 (es) 2009-04-16
PL1608346T3 (pl) 2009-07-31
EP1608346A1 (de) 2005-12-28
PT1608346E (pt) 2009-02-06

Similar Documents

Publication Publication Date Title
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
MEP18208A (en) Immune response modifier foam formulations
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
NO20073457L (no) Stabile sammensetninger av fenofibrat med fettsyreestere
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
UA83036C2 (ru) Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ
ATE439125T1 (de) Fenofibrate tablett und verfahren zur herstellung
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
TW200635925A (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
DE602006010111D1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
DE602007001373D1 (de) Verfahren zur Zubereitung von Estern des Diacereins mit Hyaluronsäure und pharmazeutische Präparate enthaltend dieselben
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
CR20230257A (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
TNSN06335A1 (en) Novel stable oral risperidone solution
BG108668A (en) Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608346

Country of ref document: EP